Evidence map›Paper›PMID 23861542›Full record

ArticleScience signaling2013

Release of nonmuscle myosin II from the cytosolic domain of tumor necrosis factor receptor 2 is required for target gene expression.

Unni M Chandrasekharan, Lisa Dechert, Uchechukwu I Davidson, Matthew Waitkus, Lori Mavrakis, Katherine Lyons, Jordan R Beach, Xiaoxia Li, Thomas T Egelhoff, Paul L Fox and 1 more

Open access · greenAbstract read
In one paragraph

Article in Science signaling, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Comprehensive analysis ofFrontiers in genetics · 2022
    Article
  2. Myosin IIA suppresses glioblastoma development in a mechanically sensitive manner.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  3. Article
  4. Article
  5. Genetic deletion of TNFR2 augments inflammatory response and blunts satellite-cell-mediated recovery response in a hind limb ischemia model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Unni M ChandrasekharanDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Lisa Dechert
Uchechukwu I Davidson
Matthew Waitkus
Lori Mavrakis
Katherine Lyons
Jordan R Beach
Xiaoxia Li
Thomas T Egelhoff
Paul L Fox
Paul E DiCorleto
Cleveland State University · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Vascular Cell function and AtherosclerosisP01HL029582 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI FOX, PAUL L · 1985 to 2019
$32.0M
Myosin Assembly in DictyosteliumR01GM050009 · NIGMS · CLEVELAND CLINIC LERNER COM-CWRU · PI EGELHOFF, THOMAS · 1998 to 2017
$4.7M
NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1TR000439NHLBI NIH HHS HL29582NHLBI NIH HHS P01 HL029582NIGMS NIH HHS R01 GM050009
6 · The paper itself

Abstract

Tumor necrosis factor-α (TNF-α) elicits its biological activities through activation of TNF receptor 1 (TNFR1, also known as p55) and TNFR2 (also known as p75). The activities of both receptors are required for the TNF-α-induced proinflammatory response. The adaptor protein TNFR-associated factor 2 (TRAF2) is critical for either p55- or p75-mediated activation of nuclear factor κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling, as well as for target gene expression. We identified nonmuscle myosin II (myosin) as a binding partner of p75. TNF-α-dependent signaling by p75 and induction of target gene expression persisted substantially longer in cells deficient in myosin regulatory light chain (MRLC; a component of myosin) than in cells replete in myosin. In resting endothelial cells, myosin was bound constitutively to the intracellular region of p75, a region that overlaps with the TRAF2-binding domain, and TNF-α caused the rapid dissociation of myosin from p75. At early time points after exposure to TNF-α, p75 activated Rho-associated kinase 1 (ROCK1). Inhibition of ROCK1 activity blocked TNF-α-dependent phosphorylation of MRLC and the dissociation of myosin from p75. ROCK1-dependent release of myosin was necessary for the TNF-α-dependent recruitment of TRAF2 to p75 and for p75-specific activation of NF-κB and MAPK signaling. Thus, our findings have revealed a previously uncharacterized, noncanonical regulatory function of myosin in cytokine signaling.

Indexed as

CytosolGene Expression RegulationHumansHuman Umbilical Vein Endothelial CellsMAP Kinase Signaling SystemMyosin Type IINF-kappa BReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIrho-Associated KinasesTNF Receptor-Associated Factor 2Tumor Necrosis Factor-alphaMyosin Type IINF-kappa BReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIrho-Associated KinasesROCK2 protein, humanTNF Receptor-Associated Factor 2Tumor Necrosis Factor-alpha

Identifiers

PMID23861542
PMCPMC3837481
OpenAlexW1980252597

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.